A General MRI-CEST Ratiometric Approach for pH Imaging: Demonstration of in Vivo pH Mapping with Iobitridol by Longo, Dario
L. et al.
A General MRI-CEST Ratiometric
Approach for pH Imaging: Demonstration
of in Vivo pH Mapping with Iobitridol
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Longo, Dario L., Phillip Zhe Sun, Lorena Consolino, Filippo C.
Michelotti, Fulvio Uggeri, and Silvio Aime. 2014. “A General MRI-
CEST Ratiometric Approach for pH Imaging: Demonstration of in
Vivo pH Mapping with Iobitridol.” Journal of the American Chemical
Society 136 (41): 14333-14336. doi:10.1021/ja5059313. http://
dx.doi.org/10.1021/ja5059313.
Published Version doi:10.1021/ja5059313
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:22856989
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
A General MRI-CEST Ratiometric Approach for pH Imaging:
Demonstration of in Vivo pH Mapping with Iobitridol
Dario L. Longo,†,# Phillip Zhe Sun,‡,# Lorena Consolino,§ Filippo C. Michelotti,§,⊥ Fulvio Uggeri,∥
and Silvio Aime*,§
†Institute of Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center and §Department of Molecular Biotechnology
and Health Sciences, Molecular Imaging Center, University of Torino, Torino 10126, Italy
‡Athinoula A. Martinos Center for Biomedical Imaging, MGH and Harvard Medical School, Charlestown, Massachusetts 02129,
United States
∥Bracco Research Center, Bracco Imaging SpA, Colleretto Giacosa, Torino 10010, Italy
*S Supporting Information
ABSTRACT: Chemical exchange saturation transfer
(CEST) is a novel contrast mechanism for magnetic
resonance imaging (MRI). CEST MRI selectively saturates
exchangeable protons that are transferred to MRI-
detectable bulk water signal. MRI-CEST (pH)-responsive
agents are probes able to map pH in the microenviron-
ment in which they distribute. To minimize the
confounding eﬀects of contrast agent concentration,
researchers have developed ratiometric CEST imaging,
which investigates contrast agents containing multiple
magnetically non-equivalent proton groups, whose proto-
tropic exchange have diﬀerent pH responses. However,
conventional ratiometric CEST MRI imposes stringent
requirements on the selection of CEST contrasts agents.
In this study, a novel ratiometric pH MRI method based
on the analysis of CEST eﬀects under diﬀerent radio
frequency irradiation power levels was developed. The
proposed method has been demonstrated using iobitridol,
an X-ray contrast agent analog of iopamidol but containing
a single set of amide protons, both in vitro and in vivo.
Magnetic resonance imaging (MRI) is widely used for invivo applications, due to its safety, spatial resolution, soft
tissue contrast, and hence, clinical relevance. Notably, MRI-
responsive contrast agents (CAs) add important physiological
information, complementing routine anatomical images. In the
past decade a new class of CAs has emerged that exploits the
chemical exchange saturation transfer (CEST) mechanism,
enabling detection of dilute solutes.1−3 Brieﬂy, following
selective radio frequency (RF) irradiation, mobile solute protons
are saturated and exchange with surrounding water molecules.
This saturation transfer results in a decrease of bulk water signal,
hence CEST-MRI contrast.4−6
Responsive agents capable of reporting physicochemical
properties of diagnostic interest of the microenvironment in
which the contrast agent distributes (such as pH, temperature,
metabolites, ions, proteins, or enzymes) have gained tremendous
attention.7−18 Notably, concentration-independent CEST
agents are needed to minimize the confounding eﬀect of
unknown and often heterogeneous distribution of contrast agent,
facilitating in vivo imaging. This has been achieved by ratiometric
CEST MRI of agents with multiple magnetically non-equivalent
protons, whose CEST eﬀects, upon ratioing, constitute the
response to the physicochemical parameters of interest
independent of contrast agent concentration.19 However,
because ratiometric CEST MRI requires selective saturation of
multiple labile groups, the chemical shift separation needs to be
relatively large.6 In addition, because the chemical shift
separation between labile proton resonances in Hz scales with
magnetic ﬁeld, ratiometric CEST imaging is particularly
challenging at low ﬁeld due to the small chemical shift diﬀerence.
Thus, development of novel means of imaging of responsive
CEST agents in vivo is urgently needed.20
Iobitridol is a widely used X-ray non-ionic contrast agent,
marketed under the trade name Xenetix (Guerbert).21 Iobitridol
is a low-osmolar non-ionic molecule, which is not charged.
Hence, it should have negligible direct eﬀects on pH measure-
ment. Iobitridol possesses a single amide group, 5.6 ppm
downﬁeld from the bulk water resonance (set at 0 ppm by
convention, Figure 1a).
The CEST properties of iobitridol were examined at diﬀerent
pH (30 mM iobitridol in PBS solution, 37 °C and B0 = 7T). Z-
spectra (Figure 1b) represent the water proton signal plotted as a
function of saturation frequency, where S0 is the control water
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Figure 1. (a) Iobitridol chemical structure with a single amide proton
group. (b) CEST spectra of 30mM iobitridol solution at pH of 5.5 (solid
line), 6.0 (dashed line), and 7.0 (dotted line). The reduction in MRI
signal from bulk water signal upon selective irradiation at 5.6 ppm is pH
sensitive (RF saturation power = 3 μT × 5 s, T = 310 K, Bo = 7 T). (c)
Numerically solved pH-dependent chemical exchange rate for labile
protons at 5.6 ppm.
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signal without RF saturation and Ssat is the signal after saturation
at a given oﬀset. Figure 1b shows that the iobitridol amide CEST
eﬀect (5.6 ppm) is indeed pH sensitive. The CEST contrast
(saturation transfer, ST) is calculated by asymmetry analysis, ST
= (S−Δω − SΔω)/S0 where S−Δω and SΔω are reference and label
signals with RF saturation applied at −Δω andΔω, respectively,
and Δω is the labile proton frequency shift from the water
resonance (i.e., 5.6 ppm for iobitridol). The iobitridol amide
proton exchange rate (kex) was determined by simultaneously
ﬁtting Z-spectra from 3 to 8 ppm, obtained under B1 power levels
of 1.5 and 3 μT, within the pH range 5.5−7.0 (Figure S1a,b).22
kex was found to be 265, 550, 1481, 2640, and 4820 Hz for pH of
5.5, 6.0, 6.3, 6.7, and 7.0, respectively. The exchange rate can be
reasonably described using a dominantly base-catalyzed
exchange regime equation (i.e., kex = k0 + kb × 10
pH‑pkw), and
we found kex = 0.96 × 10
pH−3.3 for amide protons at 5.6 ppm
(Figure 1c), similar to the 2-hydrooxypropanamido proton of
iopamidol.
It has been shown that the saturation eﬃciency for mobile
solutes can be approximately described by α ≈ ω12/(ω12 + kex2),
where ω1 is the RF irradiation power in radian (ω1 = γB1).
23 The
experimentally obtainable CEST eﬀect depends on both RF
power and kex, hence, pH.
24 We measured iobitridol CEST MRI
for a range of pH levels under three saturation power levels (1.5,
3, and 6 μT). The iobitridol CEST eﬀect is strongly pH-
dependent, as expected (Figure 2). For example, the CEST eﬀect
increased from pH of 5.5 to 6.7 and then decreased at higher pH
for a saturation power of 3 μT. We showed that the peak ST
increases and shifts to higher pH with RF power. The
observation of B1-dependent CEST measurement enables a
novel ratiometric calculation by comparing ST eﬀects obtained
under diﬀerent (two or more) RF irradiation powers from a
single labile proton group. Consequently, we propose a new
ratiometric index (dubbed ratio of RF power mismatch or RPM)
according to eq 1:
= −
−
RPM
[(1 ST)/ST)]
[(1 ST)/ST)]
RF1
RF2 (1)
where STRF1,2 represents ST obtained under diﬀerent RF power
levels (i.e., B1). The proposed RPM was calculated as a function
of pH (Figure 2b). For instance, by ratioing the ST eﬀects
between RF power levels of 3 and 6 μT, RPM showed a good pH
response for pH from 6.0 to 7.4. Moreover, RPM calculated from
RF power levels of 1.5 μT over 6 μT provided substantially
higher pH sensitivity and range, from 5.5 to 7.4.
The proposed RF power-based ratiometric analysis was
validated in vitro. Accurate iobitridol solution pH (Figure 3d)
was determined according to the pH−RPM calibration curve
(1.5/6 μT). pH determined from iobitridol CEST MRI strongly
correlates with pH-meter measurement (R2 = 0.98, P < 0.001,
Figure 3e). Similar pH determination was achieved with CEST
measurements of 3 and 6 μT (R2 = 0.97, P < 0.001, Figure S2).
It should be noted that, although RPM depends on pH and
choice of B1 power levels, it does not depend on CEST agent
concentration. This is important in order to exploit a MRI-CEST
responsive agent for in vivo applications. We prepared an
iobitridol phantom at diﬀerent concentrations in the range 10−
50 mM, with pH titrated to 6.6 and 7.2 (Figure 4). Accurate pH
values were obtained within the error limit of 0.1 pH unit for all
concentrations and pH values investigated in our study (Figure
4b,c). Concentration-independent pH was determined for RPM
analysis of both the RF power ratios of 1.5/6 μT and 3/6 μT
(Figure 4d,e).
We evaluated the proposed RPM pH imaging in vivo. Kidney
ST images (Figure 5b,c) of a wild-type BALB/c mouse were
obtained (B1 = 1.5 and 6 μT) before and 15min after intravenous
injection of iobitridol, at a typical clinical dose (1.5 g I/kg b.w.).
ST maps were calculated by taking the diﬀerence between post-
and pre-injection ST maps at 5.6 ppm, which removes
confounding endogenous CEST eﬀects (Figure S5).
Mean renal pH values between 6.4 and 6.6 were obtained, with
reasonable diﬀerentiation of the calyx-inner medulla and outer
medulla-cortical regions (Figure 5d). In our prior study the
average pH, in the same regions, varied between 6.5 and 6.7 in
healthy mice.28 Because both ratiometric pH MRI methods
Figure 2. (a) Iobitridol MRI-CEST contrast (ST%) depends on pH at
three representative RF saturation powers 1.5 (circles), 3 (squares), and
6 μT (triangles) measured at 7 T, 310 K and an irradiation time of 5 s.
(b) RPM curves provide pH-sensitive measurements: 3/6 μT
(triangles) and 1.5/6 μT (squares).
Figure 3. CEST-MR images of 30 mM iobitridol solution titrated at
diﬀerent pH values (5.5, 6.0, 6.3, 6.7, 7.0, 7.4, 7.9). ST images obtained
upon irradiation with RF saturation levels of 1.5 μT (a) and of 6 μT (b).
(c) Ratiometric RPM map calculated by using eq 1 from the ratio of the
corresponding ST images (a and b). (d) The pH map calculated from
the ratiometric map and the calibration curve of Figure 2b; and (e) pH
calculated vs pH titrated for 30 mM iobitridol phantoms, R2 = 0.98 (Bo =
7 T, 310 K).
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(iopamidol and iobitridol) have an accuracy level of about∼0.1−
0.15 units, the two sets of pH measurements appears within the
experimental error.
To further conﬁrm this issue, in vivo validation of pHMRI was
performed by comparing pH obtained with the proposed
method with that obtained with previously published iopamidol
pH mapping. A signiﬁcant correlation was found between the
two methods (Pearsons’ r = 0.90, p < 0.01), and no statistical
diﬀerence in the measured pH values was obtained between the
two methods (Figure S4).
We further investigated the proposed pH MRI method in
imaging extracellular pH in tumors. A xenograft breast tumor
mouse model was prepared by subcutaneous injection of 250,000
adenocarcinoma TSA tumor cells into both the left and right
ﬂank of a 8 weeks old BALB/c mouse.25 The mouse underwent
MRI 14 days after tumor implantation, when tumor size reached
a diameter of ∼4−6 mm. We acquired CEST images at two RF
power levels (1.5 and 6.0 μT) before and 15 min after iobitridol
injection (4 g I/kg, i.v.). ST diﬀerence maps increased by about
2−3% (B1 = 1.5 μT, Figures 6b and S6c) and 6−8% (B1 = 6 μT,
Figures 6c and S6d). The ST diﬀerence map highlights the
extravasation of iobitridol, indicating the highly heterogeneous
extracellular−extravascular space of the tumor.26 Inside tumor
regions we observed heterogeneous detectability of themolecule,
likely due to vascularization/extravasation variation within the
tumor. A similar limited extravasation was observed when using
ProHance, a Gd-based agent with equivalent small molecular
weight (Figure S7). An extracellular tumor pH of 6.4−6.8 was
measured (Figure 6d).
This study demonstrates a concentration-independent pH
imaging method that advances conventional ratiometric pH
MRI. Previously, such measurement required CEST agents with
multiple magnetically non-equivalent proton pools, such as
iopamidol and iopromide, with two labile proton pools
resonating at 4.2/4.3 ppm and 5.5/5.6 ppm, respectively, or
paramagnetic CEST agents, irradiated with the same RF
power.27−29 The method proposed herein exploits a novel
approach to RF power level-based ratiometric analysis that
extends ratiometric imaging to CEST agents with at least one
exchangeable site. The proposed pH MRI was further tested by
Figure 4. RPM pH mapping is independent of iobitridol concentration.
(a) Iobitridol-containing phantoms at diﬀerent concentrations (10−50
mM) and pH values (6.6 and 7.2). MRI-CEST pH maps calculated by
exploiting the RPM approach with RF irradiation powers of 1.5/6 μT
(b) and of 3/6 μT (c). Mean pH values calculated for several
concentrations upon ratioing 1.5/6 μT (d) and of 3/6 μT (e).
Figure 5. Renal CEST-MRI following iobitridol i.v. injection (1.5 g I/kg
b.w.). (a) T2w renal MRI. CEST ST diﬀerence map between pre-/post-
injection at 1.5 μT (b) and 6 μT (c). (d) The pH map determined from
RF power-based ratiometric pH imaging. Only kidney signal displayed
in color on grayscale image to highlight eﬀects.
Figure 6. CEST-MR images of xenografted-tumor bearing mouse
following iobitridol i.v. injection (dose 4 g I/kg b.w.). (a) T2w anatomical
image with ROIs including the two tumors; CEST contrast diﬀerence
map between pre- and post-injection following RF irradiation at 1.5 μT
(b) and at 6 μT (c). (d) Corresponding pHmap obtained upon ratioing
the diﬀerence ST maps of (b and c). Only tumor signal displayed in
color on grayscale image to highlight eﬀects.
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measuring pH with iobitridol concentration ranging from 10 to
50 mM. Indeed, pH determination was within pH of 0.1 (Figure
4d,e), conﬁrming that the proposed method provides concen-
tration-independent pH measurement.
The proposed iobitridol pH MRI method covers a broad pH
range, slightly higher than that achieved with conventional
ratiometric pH MRI.9,30,31 We calculated the diﬀerence of the
ratiometric values between the pH values of 6.0 and 7.4 (ΔRpH)
to assess pH sensitivity and foundΔRpH to be 3.1, 2.8, and 1.1 for
iopamidol, iopromide, and YbHPDO3A, respectively, while the
proposed iobitridol pH MRI method yielded ΔRpH of 2.7 (3/6
μT) and 11.6 (1.5/6 μT, Figure S3).
Further study is needed to optimize this new pHMRImethod.
Our study investigated typical RF power levels of 1.5, 3, and 6 μT,
which could be further investigated for enhanced pH
sensitivity.32,33 Whereas only one Z-spectrum is needed to
derive pH from conventional ratiometric pH MRI, our approach
requires two Z-spectra. Whereas contrast agent concentration
change between two Z-spectra may aﬀect pH determination in
vivo, we observed that small concentration diﬀerence due to
washout does not signiﬁcantly aﬀect pH measurement (Figure
S8). Because the chemical shift diﬀerence between water and
labile protons (e.g., 5.6 ppm for iobitridol) is much larger than
chemical shift diﬀerence between labile groups (e.g., 1.2 ppm for
iopamidol), the proposed approach should be more applicable at
lower ﬁeld strength.
Thus, the proposed RF power-based ratiometric pH MRI
method extends conventional ratiometric pHMRI, enhances pH
sensitivity, and is promising to facilitate in vivo pH imaging.34
Importantly, iobitridol has been approved for human use, and the
possibility of imaging iodinated X-ray contrast media as MRI-
CEST agents in patient has been recently reported.35 In
conclusion, our study generalizes conventional ratiometric
CEST-MRI and is promising for a host of molecular imaging
applications.
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